Regulatory-arkiv - Page 2 of 13

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

GOTHENBURG, Sweden, February 24, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company’s […]

GOTHENBURG, Sweden, February 18, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that

GOTHENBURG, Sweden, November 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that

GOTHENBURG, Sweden, November 4, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that

GOTHENBURG, Sweden, August 26, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report

GOTHENBURG, Sweden, July 31, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes

GOTHENBURG, Sweden, 4 July 2025 – Isofol Medical AB (“Isofol” or the “Company”) today announces the outcome of the Company’s

GOTHENBURG, Sweden, 17 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol” or

GOTHENBURG, 11 June 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at

GOTHENBURG, Sweden, 5 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or